JP2021530233A5 - - Google Patents

Info

Publication number
JP2021530233A5
JP2021530233A5 JP2021502538A JP2021502538A JP2021530233A5 JP 2021530233 A5 JP2021530233 A5 JP 2021530233A5 JP 2021502538 A JP2021502538 A JP 2021502538A JP 2021502538 A JP2021502538 A JP 2021502538A JP 2021530233 A5 JP2021530233 A5 JP 2021530233A5
Authority
JP
Japan
Prior art keywords
amino acid
sequence
seq
acid residues
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021502538A
Other languages
English (en)
Japanese (ja)
Other versions
JP7459046B2 (ja
JP2021530233A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042245 external-priority patent/WO2020018695A1/en
Publication of JP2021530233A publication Critical patent/JP2021530233A/ja
Publication of JP2021530233A5 publication Critical patent/JP2021530233A5/ja
Application granted granted Critical
Publication of JP7459046B2 publication Critical patent/JP7459046B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021502538A 2018-07-18 2019-07-17 Ｓｔｅａｐ１に対するキメラ受容体及びその使用方法 Active JP7459046B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862700178P 2018-07-18 2018-07-18
US62/700,178 2018-07-18
PCT/US2019/042245 WO2020018695A1 (en) 2018-07-18 2019-07-17 Chimeric receptors to steap1 and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021530233A JP2021530233A (ja) 2021-11-11
JP2021530233A5 true JP2021530233A5 (enExample) 2022-07-26
JP7459046B2 JP7459046B2 (ja) 2024-04-01

Family

ID=67515138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502538A Active JP7459046B2 (ja) 2018-07-18 2019-07-17 Ｓｔｅａｐ１に対するキメラ受容体及びその使用方法

Country Status (24)

Country Link
US (2) US20210277148A1 (enExample)
EP (1) EP3823993A1 (enExample)
JP (1) JP7459046B2 (enExample)
KR (2) KR20260017491A (enExample)
CN (2) CN112771080B (enExample)
AR (1) AR117950A1 (enExample)
AU (1) AU2019307607B2 (enExample)
BR (1) BR112021000914A2 (enExample)
CA (1) CA3106653A1 (enExample)
CL (3) CL2021000136A1 (enExample)
CO (1) CO2021000660A2 (enExample)
CR (1) CR20210091A (enExample)
EA (1) EA202190304A1 (enExample)
IL (2) IL324856A (enExample)
JO (1) JOP20210011A1 (enExample)
MA (1) MA53167A (enExample)
MX (2) MX2021000617A (enExample)
PE (1) PE20210315A1 (enExample)
PH (1) PH12021550120A1 (enExample)
SA (1) SA521421049B1 (enExample)
SG (1) SG11202100464UA (enExample)
TW (2) TWI860294B (enExample)
UY (1) UY38309A (enExample)
WO (1) WO2020018695A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3817770T3 (fi) * 2018-07-02 2026-07-06 Amgen Inc Antigeeniä sitova anti-steap1-proteiini
EP4433512A4 (en) * 2021-11-19 2025-12-31 Univ Pennsylvania Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy
EP4476267A4 (en) * 2022-02-11 2026-01-07 Fred Hutchinson Cancer Center CHIMERIC ANTIGENIC RECEPTORS BINDING TO STEAP1
GB202208119D0 (en) * 2022-06-01 2022-07-13 Univ Oslo Hf Anti-steap1 car
CN116178532B (zh) * 2023-01-30 2025-04-04 中国科学院武汉病毒研究所 一种古尔图病毒核蛋白的单克隆抗体及其应用
AU2024274301A1 (en) * 2023-05-16 2025-12-11 Fred Hutchinson Cancer Center Pro-inflammatory cytokine enhanced steap1 recombinant receptors
WO2025090749A1 (en) * 2023-10-25 2025-05-01 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors targeting leucine rich repeat containing 15 (lrrc15)
CN121449740A (zh) * 2024-08-01 2026-02-03 南京蓬勃生物科技有限公司 一种结合steap1的抗体或其抗原结合部分及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE69941187D1 (de) * 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
AU2472400A (en) * 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
PT2845866T (pt) * 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9024028B2 (en) 2011-01-26 2015-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for the synthesis of multimerizing agents
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2014059173A2 (en) * 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
WO2014165818A2 (en) * 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
CA2912389C (en) * 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CN107074957B (zh) * 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
WO2015112909A1 (en) * 2014-01-24 2015-07-30 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
CA2957929A1 (en) * 2014-08-12 2016-02-18 Anthrogenesis Corporation Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
US10017577B2 (en) * 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
WO2017055388A2 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
GB201518136D0 (en) * 2015-10-14 2015-11-25 Glaxosmithkline Ip Dev Ltd Novel chimeric antigen receptors
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
FI3817770T3 (fi) * 2018-07-02 2026-07-06 Amgen Inc Antigeeniä sitova anti-steap1-proteiini

Similar Documents

Publication Publication Date Title
JP2021520788A5 (enExample)
JP2022523781A5 (enExample)
JP2019516352A5 (enExample)
HRP20221348T1 (hr) Kimerni receptori i postupci njihove uporabe
JP2021000103A5 (enExample)
JP2019515661A5 (enExample)
RU2017105160A (ru) Лечение рака с помощью химерного антигенного рецептора к cd33
IL277398B2 (en) Pd-l1 binding affimers, and uses related thereto
JP2022530773A5 (enExample)
RU2017105065A (ru) Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
RU2017105161A (ru) Лечение рака с использованием химерного антигенного рецептора cll-1
JP2017522879A5 (enExample)
JP2019523301A5 (enExample)
JP2022538425A5 (enExample)
JP2023518930A5 (enExample)
JP2019516350A5 (enExample)
JP2018538339A5 (enExample)
RU2019128921A (ru) Антитело к il-13ra2 и его применение
JP2024539506A5 (enExample)
JP2018527014A5 (enExample)
JP2024517027A5 (enExample)
JP2025513427A5 (enExample)
JP2025511409A5 (enExample)
US20240067955A1 (en) Methods for high throughput screening of chimeric antigen receptors
JP2024511423A5 (enExample)